ElShereef C, Zaki H, Badary O, Kamal S, Nagy M, Makhlouf D
Asian Pac J Cancer Prev. 2024; 25(7):2445-2455.
PMID: 39068579
PMC: 11480601.
DOI: 10.31557/APJCP.2024.25.7.2445.
Zhang L, Li X, Chen L, Chen Z, Xu R, Qian J
Heliyon. 2024; 10(7):e28952.
PMID: 38596098
PMC: 11002277.
DOI: 10.1016/j.heliyon.2024.e28952.
Wang P, Sharma A, Montana M, Neiner A, Juriga L, Reddy K
Br J Clin Pharmacol. 2022; 88(11):4881-4893.
PMID: 35538637
PMC: 10908252.
DOI: 10.1111/bcp.15393.
Desta Z, El-Boraie A, Gong L, Somogyi A, Lauschke V, Dandara C
Clin Pharmacol Ther. 2021; 110(1):82-97.
PMID: 33448339
PMC: 8693800.
DOI: 10.1002/cpt.2166.
Wang T, Du H, Ma J, Shen L, Wei M, Zhao X
PeerJ. 2020; 8:e9628.
PMID: 32821545
PMC: 7397980.
DOI: 10.7717/peerj.9628.
Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants.
Wang P, Neiner A, Kharasch E
Drug Metab Dispos. 2020; 48(6):438-445.
PMID: 32238417
PMC: 7228493.
DOI: 10.1124/dmd.119.090407.
Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity.
Singh H, Lata S, Dhole T, Gangakhedkar R
Mol Genet Genomic Med. 2019; 7(4):e00598.
PMID: 30864294
PMC: 6465650.
DOI: 10.1002/mgg3.598.
Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.
Ahmad T, Sabet S, Primerano D, Richards-Waugh L, Rankin G
J Anal Toxicol. 2017; 41(4):325-333.
PMID: 28184434
PMC: 5412025.
DOI: 10.1093/jat/bkw135.
CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide.
Labib R, Abdelrahim M, Elnadi E, Hesham R, Yassin D
PLoS One. 2016; 11(7):e0158890.
PMID: 27388155
PMC: 4936837.
DOI: 10.1371/journal.pone.0158890.
Functional Characterization of Human CYP2C9 Allelic Variants in COS-7 Cells.
Du H, Wei Z, Yan Y, Xiong Y, Zhang X, Shen L
Front Pharmacol. 2016; 7:98.
PMID: 27199745
PMC: 4843492.
DOI: 10.3389/fphar.2016.00098.
Differences in Methadone Metabolism by CYP2B6 Variants.
Gadel S, Friedel C, Kharasch E
Drug Metab Dispos. 2015; 43(7):994-1001.
PMID: 25897175
PMC: 4468442.
DOI: 10.1124/dmd.115.064352.
CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.
Carr D, Chaponda M, Cornejo Castro E, Jorgensen A, Khoo S, van Oosterhout J
J Antimicrob Chemother. 2014; 69(12):3329-34.
PMID: 25147095
PMC: 4228781.
DOI: 10.1093/jac/dku315.
Evaluation of influence of single nucleotide polymorphisms in cytochrome P450 2B6 on substrate recognition using computational docking and molecular dynamics simulation.
Kobayashi K, Takahashi O, Hiratsuka M, Yamaotsu N, Hirono S, Watanabe Y
PLoS One. 2014; 9(5):e96789.
PMID: 24796891
PMC: 4010486.
DOI: 10.1371/journal.pone.0096789.
CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.
Xu C, Quinney S, Guo Y, Hall S, Li L, Desta Z
Drug Metab Dispos. 2013; 41(12):2004-11.
PMID: 23846872
PMC: 3834132.
DOI: 10.1124/dmd.113.051755.
Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance.
Zanger U, Klein K
Front Genet. 2013; 4:24.
PMID: 23467454
PMC: 3588594.
DOI: 10.3389/fgene.2013.00024.
Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.
Gadel S, Crafford A, Regina K, Kharasch E
Drug Metab Dispos. 2013; 41(4):709-13.
PMID: 23298862
PMC: 3608451.
DOI: 10.1124/dmd.112.050625.
Biotransformation of BDE-47 to potentially toxic metabolites is predominantly mediated by human CYP2B6.
Feo M, Gross M, McGarrigle B, Eljarrat E, Barcelo D, Aga D
Environ Health Perspect. 2012; 121(4):440-6.
PMID: 23249762
PMC: 3620761.
DOI: 10.1289/ehp.1205446.
Cytochrome P450 2B diversity and dietary novelty in the herbivorous, desert woodrat (Neotoma lepida).
Malenke J, Magnanou E, Thomas K, Dearing M
PLoS One. 2012; 7(8):e41510.
PMID: 22927909
PMC: 3425548.
DOI: 10.1371/journal.pone.0041510.
Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.
Li J, Menard V, Benish R, Jurevic R, Guillemette C, Stoneking M
Pharmacogenomics. 2012; 13(5):555-70.
PMID: 22462748
PMC: 3390746.
DOI: 10.2217/pgs.11.160.
Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Xu C, Ogburn E, Guo Y, Desta Z
Drug Metab Dispos. 2012; 40(4):717-25.
PMID: 22232427
PMC: 3310426.
DOI: 10.1124/dmd.111.042416.